


AZD6244

STUDY 16

In advanced or metastatic non-small-cell lung cancer

A Phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of AZD6244 (hyd-sulfate) in combination with docetaxel, compared with docetaxel alone, in second-line patients with *KRAS* mutation positive local advanced or metastatic non-small-cell lung cancer (Stage IIIB - IV)



Purpose: To assess the efficacy in terms of progression-free survival of AZD6244 in combination with docetaxel compared with docetaxel alone

Primary endpoint: Progression-free survival

Secondary endpoints: Overall survival, objective response rate, duration of response, change in tumor size at 12 weeks, alive and progression-free at 6 months, safety and tolerability, PK, investigate the use of plasma and serum as a potential source of CFDNA for the analysis of *KRAS* mutation status

Participating countries: Belgium | Brazil | Canada | Czech Republic | Denmark | France | Hungary | Italy | Mexico | Peru | Spain | United States

AZD6244 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.

For more information,
please contact:

Cancer Study Locator service, sponsored by
AstraZeneca at 1-877-400-4656
Or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov

AstraZeneca 

AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware
www.astrazeneca.com